Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net sales	$ 651.6	$ 638.5	$ 1,237.0	$ 1,249.3
Cost of goods sold	306.3	283.4	585.7	568.2
Gross profit	345.3	355.1	651.3	681.1
Selling, general and administrative expense	207.7	194.7	416.5	409.6
Research and Development Expense	60.5	58.9	134.0	125.3
Segment profit (loss)	77.1	101.5	100.8	146.2
Interest expense	12.6	12.3	24.6	24.5
Foreign exchange (gains) losses, net	1.1	(1.7)	(1.6)	(3.7)
Marketable Securities, Unrealized (Gain) Loss	(334.4)	2,895.4	(366.2)	2,473.2
Other Nonoperating Income (Expense)	16.2	18.2	53.4	52.6
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	414.0	(2,786.3)	497.4	(2,295.2)
(Provision) benefit for income taxes	(96.2)	620.8	(115.6)	513.6
Net income attributable to Bio-Rad	$ 317.8	$ (2,165.5)	$ 381.8	$ (1,781.6)
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 11.67	$ (76.26)	$ 13.84	$ (62.61)
Weighted average common shares - basic	27,226	28,395	27,581	28,457
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 11.67	$ (76.26)	$ 13.84	$ (62.61)
Weighted average common shares - diluted	27,228	28,395	27,589	28,457